Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines for the treatment of eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. Its products include injections to treat macular edema, moderate-to-severe atopic dermatitis, heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, rheumatoid arthritis. The company also offers injections to treat cryopyrin-associated periodic syndromes and metastatic colorectal cancer. In addition, it develops a trap-based clinical product for the treatment of neovascular glaucoma, and antibody-based clinical programs.
Type | Public | |
Founded | 1988 | |
HQ | Tarrytown, NY, US | Map |
Website | regeneron.com | |
Employee Ratings | More | |
Overall Culture | C+ | More |
USD | |
---|---|
Revenue (FY, 2020) | 8.5b |
Net income (FY, 2020) | 3.5b |
EBIT (FY, 2020) | 3.6b |
Market capitalization (8-Feb-2021) | 52.8b |
Closing stock price (8-Feb-2021) | 494.9 |
Cash (31-Dec-2020) | 2.2b |
EV | 53.3b |
USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.3b | 1.5b | 1.5b | 1.5b | 1.6b | 1.7b | 1.7b | 1.9b | 2.0b | 1.8b | 1.2b | 1.5b |
Cost of goods sold | 84.2m | 102.9m | 104.2m | 114.9m | 91.7m | 110.4m | 179.2m | 152.5m | 226.6m | 102.5m | ||
Gross profit | 1.2b | 1.4b | 1.4b | 1.4b | 1.5b | 1.6b | 1.5b | 1.8b | 1.8b | 1.1b | ||
Gross profit Margin, % | 94% | 93% | 93% | 92% | 94% | 93% | 90% | 92% | 89% | 92% |
USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 811.8m | 744.3m | 792.1m | 1.0b | 917.9m | 1.1b | 1.7b | 1.0b | 1.4b | 2.2b | 2.0b | 1.6b |
Accounts Receivable | 1.7b | 1.8b | 2.0b | 1.9b | 2.0b | 2.2b | 2.3b | 2.5b | 2.7b | 2.1b | 431.1m | 3.1b |
Prepaid Expenses | 146.1m | 193.3m | 143.8m | 155.5m | 163.6m | 284.8m | 182.2m | 208.2m | 226.9m | 226.6m | 263.8m | 230.6m |
Inventories | 466.6m | 554.3m | 641.6m | 820.4m | 928.6m | 1.0b | 1.2b | 1.3b | 1.3b | 1.5b | 1.6b | 1.8b |
USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 248.9m | 636.7m | 1.0b | 478.0m | 1.0b | 1.6b | 461.1m | 654.2m | 1.3b | 624.6m | 1.5b | |
Depreciation and Amortization | 38.1m | 73.2m | 111.0m | 36.4m | 70.0m | 105.4m | 51.0m | 103.1m | 156.0m | 56.1m | 114.9m | 174.2m |
Inventories | (69.7m) | (151.5m) | (235.6m) | (88.8m) | (182.1m) | (281.6m) | (58.6m) | (168.2m) | (227.2m) | (70.8m) | (233.4m) | (402.4m) |
Accounts Payable | 187.7m | (147.2m) | (28.9m) | 76.7m | 67.0m | 179.9m | (19.6m) | 110.3m | 119.9m | (85.2m) | 20.9m | 80.8m |
USD | FY, 2016 |
---|---|
Revenue/Employee | 900.1k |
Debt/Equity | 0.1 x |
Debt/Assets | 0.1 x |
Financial Leverage | 1.6 x |
Company Name | Date | Deal Size |
---|---|---|
Loop Road Holdings LLC | ||
Old Saw Mill Holdings LLC | ||
OSMR Holdings | ||
OSMR International | ||
OSMR LLC | ||
Regeneron Assurance | ||
Regeneron Atlantic Holdings | ||
Regeneron Belgium BVBA | ||
Regeneron Capital International B.V. | ||
Regeneron Genetics Center LLC |
Regeneron Pharmaceuticals revenue breakdown by business segment: 33.3% from Sanofi and Bayer Collaboration, 61.5% from Product Sales and 5.3% from Other
Regeneron Pharmaceuticals has 27.47k Twitter Followers. The number of followers has increased 0.1% month over month and increased 3.1% quarter over quarter
4.3k
Tweets
301
Following
27.5k
Followers
33
Tweets last 30 days
22.9
Avg. likes per Tweet
100%
Tweets with engagement
C+
73/100
C+
72/100
B-
74/100
When was Regeneron Pharmaceuticals founded?
Regeneron Pharmaceuticals was founded in 1988.
Who are Regeneron Pharmaceuticals key executives?
Regeneron Pharmaceuticals's key executives are Leonard S. Schleifer, George D. Yancopoulos and Nouhad Husseini.
How many employees does Regeneron Pharmaceuticals have?
Regeneron Pharmaceuticals has 8,100 employees.
What is Regeneron Pharmaceuticals revenue?
Latest Regeneron Pharmaceuticals annual revenue is $8.5 b.
What is Regeneron Pharmaceuticals revenue per employee?
Latest Regeneron Pharmaceuticals revenue per employee is $1 m.
Who are Regeneron Pharmaceuticals competitors?
Competitors of Regeneron Pharmaceuticals include Catalent, Bristol-Myers Squibb and Idorsia.
Where is Regeneron Pharmaceuticals headquarters?
Regeneron Pharmaceuticals headquarters is located at 777 Old Saw Mill River Rd, Tarrytown.
Where are Regeneron Pharmaceuticals offices?
Regeneron Pharmaceuticals has offices in Tarrytown, Bernards, Rensselaer, Sleepy Hollow and in 4 other locations.
How many offices does Regeneron Pharmaceuticals have?
Regeneron Pharmaceuticals has 8 offices.
Receive alerts for 300+ data fields across thousands of companies